General amyloid interaction motif (GAIM)
AssigneeAmyl Therapeutics SRL
InventorsRajaraman Krishnan, Eva Asp, Ming Proschitsky, Richard Fisher
Life of this patent
Estimating the term…
Loading patent…
AssigneeAmyl Therapeutics SRL
InventorsRajaraman Krishnan, Eva Asp, Ming Proschitsky, Richard Fisher
Estimating the term…
The present invention relates to variants of the general amyloid interaction motif (GAIM) of bacteriophage gene 3 protein (g3p) and fusion proteins thereof. The GAIM variants and fusion proteins of the invention are partially or fully deimmunized and demonstrate superior binding and specificity to a diverse array of amyloid proteins, and exhibit enhanced amyloid remodeling and inhibition of amyloid aggregation. The present invention further relates to nucleic acids, vectors, host cells, and methods of making the GAIM variants and fusion proteins thereof. The present invention also relates to pharmaceutical compositions and methods of increasing bacteriophage infectivity, methods of detecting amyloid aggregates, and methods of diagnosing and/or treating a disease associated with misfolded and/or aggregated amyloid protein.
A polypeptide comprising a variant of starting amino acid sequence SEQ ID NO:16, wherein the variant differs from SEQ ID NO:16 by one or more sets of amino acid changes selected from:
Dependencies are inferred from the claim text.